This report is prepared solely

This report is prepared solely

for the use of John Strumbos

212-497-0856/310-473-2942

PM Corner: A Conversation With RTW's Rod Wong

We find ourselves struggling with

the vast expanse of biotech these days, so we thought we'd elicit help from the experts!

is the founder and Managing Partner of RTW Investments, which has been in the news lately-its SPAC merged with Roivant's

Immunovant (developing a s.c. FcRN antibody) and it also announced the launch a venture fund on the London Stock Exchange.

emerged as one of the leading life science dedicated funds, so makes for a great starting point for our new series entitled "PM

Question: Can you give us a snapshot

Question: With the proliferation of

biotech companies over the past few year, has your investment approach/strategy changed? If so, how?

Question: Do you find yourself going

as deep into companies as you used to? If yes, how do you choose which to drill into? If no, how do you manage heightened risks

Click on note for full conversation

see the analyst certification and important disclosures on page 2 of this report. Evercore ISI and affiliates do and seek to do

business with companies covered in its research reports. Investors should be aware that the firm may have a conflict of interest

that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their

investment decision.

This report is prepared solely for the use of John Strumbos

Do you find yourself going as deep into companies as you used to? If yes, how do you choose which to drill into? If no, how do

you manage heightened risks of less analysis?

With lots of everything' (so many competitive bispecifics, CARs, gene therapy etc) how do you navigate? What criteria

What do you think are the most positive and negative changes within the industry over the past 5-10 years?

Heading into an election year, how are you generally positioning within biotech especially with all the noise around drug pricing?

What do you see as the biggest risks and opportunities for the sector?

This report is prepared solely for the use of John Strumbos

Favorite investment themes? Top investment avoids'?

Are you concerned that the biotech industry doesn't really return capital to investors outside of M&A? Is that something

you think should change or is "business as usual" copacetic?

How was the experience starting a SPAC? Did you know Immuvant would likely be the target company? Plans to do this again?

What was the objective/purpose of the new London fund?

Are you still participating in IPOs? How often do you participate in IPOs where you weren't in the crossover? Where you

were in the crossover?

This report is prepared solely for the use of John Strumbos

Best thing you've done in 2019? One thing you regret most in 2019?

you Rod! Appreciate your thoughtful insights. Stay tuned for more from our PM Corner series ideas for topics are always

This report is prepared solely for the use of John Strumbos

3(1)e and Article 7 of MAR)

of dissemination: October 28 2019 01:04

analysts, Josh Schimmer, Ravi Mehrotra, Neeraj Koduri , Angela Ni, Maneka Mirchandaney, primarily responsible for the preparation

of this research report attest to the following: (1) that the views and opinions rendered in this research report reflect his

or her personal views about the subject companies or issuers; and (2) that no part of the research analyst's compensation

was, is, or will be directly related to the specific recommendations or views in this research report.

report is approved and/or distributed by Evercore Group L.L.C. ("Evercore Group"), a U.S. licensed broker-dealer regulated

by the Financial Industry Regulatory Authority ("FINRA"), and Evercore ISI International Limited ("ISI UK''), which

is authorised and regulated in the United Kingdom by the Financial Conduct Authority. The institutional sales, trading and research

businesses of Evercore Group and ISI UK collectively operate under the global marketing brand name Evercore ISI ("Evercore

ISI"). Both Evercore Group and ISI UK are subsidiaries of Evercore Inc. ("Evercore"). The trademarks, logos and

service marks shown on this report are registered trademarks of Evercore.

analysts and associates responsible for preparing this report receive compensation based on various factors, including Evercore's

Partners' total revenues, a portion of which is generated by affiliated investment banking transactions. Evercore ISI seeks to

update its research as appropriate, but various regulations may prevent this from happening in certain instances. Aside from certain

industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate

in the analyst's judgment.

ISI generally prohibits analysts, associates and members of their households from maintaining a financial interest in the securities

of any company in the analyst's area of coverage. Any exception to this policy requires specific approval by a member of our Compliance

Department. Such ownership is subject to compliance with applicable regulations and disclosure. Evercore ISI also prohibits analysts,

associates and members of their households from serving as an officer, director, advisory board member or employee of any company

that the analyst covers.

report may include a Tactical Call, which describes a near-term event or catalyst affecting the subject company or the market

overall and which is expected to have a short-term price impact on the equity shares of the subject company. This Tactical Call

is separate from the analyst's long-term recommendation (Outperform, In Line or Underperform) that reflects a stock's forward

12-month expected return, is not a formal rating and may differ from the target prices and recommendations reflected in the analyst's

current disclosures regarding the subject companies covered in this report are available at the offices of Evercore ISI, and can

be obtained by writing to Evercore Group L.L.C., Attn. Compliance, 666 Fifth Avenue, 11th Floor, New York, NY 10103.

and its affiliates, and I or their respective directors, officers, members and employees, may have, or have had, interests or

qualified holdings on issuers mentioned in this report. Evercore and its affiliates may have, or have had, business relationships

with the companies mentioned in this report.

information on securities or financial instruments mentioned in this report is available upon request.

ISI's recommendations are based on a stock's total forecasted return over the next 12 months. Total forecasted return is equal

to the expected percentage price return plus gross dividend yield. We divide our stocks under coverage into three primary ratings

categories, with the following return guidelines:

the total forecasted return is expected to be greater than the expected total return of the analyst's coverage universe

Line- the total forecasted return is expected to be in line with the expected total return of the analyst's universe

the total forecasted return is expected to be less than the expected total return of the analyst's universe

Suspended- the rating and target price have been removed pursuant to Evercore ISI policy when Evercore is acting in an advisory

capacity in a merger or strategic transaction involving this company and in certain other circumstances.*

Suspended- Evercore ISI has suspended the rating and target price for this stock because there is not sufficient fundamental

basis for determining, or there are legal, regulatory or policy constraints around publishing, a rating or target price. The previous

rating and target price, if any, are no longer in effect for this company and should not be relied upon.*

to October 10, 2015, the "Coverage Suspended" and "Rating Suspended" categories were included in the category

This report is prepared solely for the use of John Strumbos

requires that members who use a ratings system with terms other than "Buy," "Hold/Neutral" and "Sell"

to equate their own ratings to these categories. For this purpose, and in the Evercore ISI ratings distribution below, our Outperform,

In Line, and Underperform ratings can be equated to Buy, Hold and Sell, respectively.

to March 2, 2017, Evercore ISI's recommendations were based on a stock's total forecasted return over the next 12 months:

the total forecasted return is expected to be greater than 10%

the total forecasted return is expected to be greater than or equal to 0% and less than or equal to 10%

-the total forecasted return is expected to be less than 0%

October 31, 2014, Evercore acquired International Strategy & Investment Group LLC ("ISI Group") and ISI UK (the

"Acquisition") and transferred Evercore Group's research, sales and trading businesses to ISI Group. On December 31,

2015, the combined research, sales and trading businesses were transferred back to Evercore Group in an internal reorganization.

Since the Acquisition, the combined research, sales and trading businesses have operated under the global marketing brand name

to October 10, 2014, the ratings system of ISI Group and ISI UK which was based on a 12-month risk adjusted total return: